| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2013-06-18 18:41:57 UTC |
|---|
| Update Date | 2019-07-23 07:14:49 UTC |
|---|
| HMDB ID | HMDB0060666 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Endoxifen |
|---|
| Description | Endoxifen (EDX) is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptors that also inhibits aromatase activity. (PMID: 23274567 ) Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia ) The pharmacological activity of Tamoxifen is dependent on its conversion to its active metabolite, endoxifen, by CYP2D6. (PMID: 23711794 ) Tamoxifen is a largely inactive pro-drug, requiring metabolism into its most important metabolite endoxifen. Since the cytochrome P450 (CYP) 2D6 enzyme is primarily involved in this metabolism, genetic polymorphisms of this enzyme, but also drug-induced CYP2D6 inhibition can result in considerably reduced endoxifen formation and as a consequence may affect the efficacy of tamoxifen treatment. (PMID: 23760858 ) |
|---|
| Structure | CC\C(=C(/C1=CC=C(O)C=C1)C1=CC=C(OCCNC)C=C1)C1=CC=CC=C1 InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24- |
|---|
| Synonyms | | Value | Source |
|---|
| 4-Hydroxy-N-desmethyltamoxifen | Kegg | | 4-Hydroxy-N-demethyltamoxifen | HMDB | | 4-Hydroxy-N-desmethyltamoxifen, (Z)-isomer | HMDB | | Z-Endoxifen | MeSH |
|
|---|
| Chemical Formula | C25H27NO2 |
|---|
| Average Molecular Weight | 373.4874 |
|---|
| Monoisotopic Molecular Weight | 373.204179113 |
|---|
| IUPAC Name | 4-[(1Z)-1-{4-[2-(methylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol |
|---|
| Traditional Name | endoxifen |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CC\C(=C(/C1=CC=C(O)C=C1)C1=CC=C(OCCNC)C=C1)C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24- |
|---|
| InChI Key | MHJBZVSGOZTKRH-IZHYLOQSSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Phenylpropanoids and polyketides |
|---|
| Class | Stilbenes |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Stilbenes |
|---|
| Alternative Parents | |
|---|
| Substituents | - Stilbene
- Diphenylmethane
- Phenylpropane
- Phenoxy compound
- Phenol ether
- Alkyl aryl ether
- 1-hydroxy-2-unsubstituted benzenoid
- Phenol
- Monocyclic benzene moiety
- Benzenoid
- Secondary amine
- Ether
- Secondary aliphatic amine
- Organic oxygen compound
- Amine
- Organooxygen compound
- Organonitrogen compound
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 8.58 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 15.0529 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.29 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2468.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 308.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 223.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 198.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 332.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 712.9 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 622.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 154.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1401.4 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 586.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1500.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 449.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 419.9 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 239.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 220.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Endoxifen,1TMS,isomer #1 | CC/C(=C(/C1=CC=C(OCCNC)C=C1)C1=CC=C(O[Si](C)(C)C)C=C1)C1=CC=CC=C1 | 3311.9 | Semi standard non polar | 33892256 | | Endoxifen,1TMS,isomer #2 | CC/C(=C(\C1=CC=C(O)C=C1)C1=CC=C(OCCN(C)[Si](C)(C)C)C=C1)C1=CC=CC=C1 | 3531.5 | Semi standard non polar | 33892256 | | Endoxifen,2TMS,isomer #1 | CC/C(=C(/C1=CC=C(OCCN(C)[Si](C)(C)C)C=C1)C1=CC=C(O[Si](C)(C)C)C=C1)C1=CC=CC=C1 | 3472.9 | Semi standard non polar | 33892256 | | Endoxifen,2TMS,isomer #1 | CC/C(=C(/C1=CC=C(OCCN(C)[Si](C)(C)C)C=C1)C1=CC=C(O[Si](C)(C)C)C=C1)C1=CC=CC=C1 | 3160.9 | Standard non polar | 33892256 | | Endoxifen,2TMS,isomer #1 | CC/C(=C(/C1=CC=C(OCCN(C)[Si](C)(C)C)C=C1)C1=CC=C(O[Si](C)(C)C)C=C1)C1=CC=CC=C1 | 3707.9 | Standard polar | 33892256 | | Endoxifen,1TBDMS,isomer #1 | CC/C(=C(/C1=CC=C(OCCNC)C=C1)C1=CC=C(O[Si](C)(C)C(C)(C)C)C=C1)C1=CC=CC=C1 | 3541.4 | Semi standard non polar | 33892256 | | Endoxifen,1TBDMS,isomer #2 | CC/C(=C(\C1=CC=C(O)C=C1)C1=CC=C(OCCN(C)[Si](C)(C)C(C)(C)C)C=C1)C1=CC=CC=C1 | 3744.9 | Semi standard non polar | 33892256 | | Endoxifen,2TBDMS,isomer #1 | CC/C(=C(/C1=CC=C(OCCN(C)[Si](C)(C)C(C)(C)C)C=C1)C1=CC=C(O[Si](C)(C)C(C)(C)C)C=C1)C1=CC=CC=C1 | 3896.8 | Semi standard non polar | 33892256 | | Endoxifen,2TBDMS,isomer #1 | CC/C(=C(/C1=CC=C(OCCN(C)[Si](C)(C)C(C)(C)C)C=C1)C1=CC=C(O[Si](C)(C)C(C)(C)C)C=C1)C1=CC=CC=C1 | 3568.0 | Standard non polar | 33892256 | | Endoxifen,2TBDMS,isomer #1 | CC/C(=C(/C1=CC=C(OCCN(C)[Si](C)(C)C(C)(C)C)C=C1)C1=CC=C(O[Si](C)(C)C(C)(C)C)C=C1)C1=CC=CC=C1 | 3850.1 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Endoxifen GC-MS (Non-derivatized) - 70eV, Positive | splash10-0006-9133000000-c2161354cdf77d434e99 | 2017-09-20 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Endoxifen GC-MS (1 TMS) - 70eV, Positive | splash10-0006-9004200000-3d59e8fe230516e4b37b | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Endoxifen GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Endoxifen GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Endoxifen 10V, Positive-QTOF | splash10-00di-2249000000-8346297433ff370f4efc | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Endoxifen 20V, Positive-QTOF | splash10-0a4i-9353000000-c4a46698f9bb9d64a6a3 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Endoxifen 40V, Positive-QTOF | splash10-0a4l-9251000000-f988f5670acac5e08df6 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Endoxifen 10V, Negative-QTOF | splash10-00di-1009000000-62ed97feda2a9f20b6ac | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Endoxifen 20V, Negative-QTOF | splash10-01b9-1019000000-b6b443507b9eb725195a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Endoxifen 40V, Negative-QTOF | splash10-014i-6297000000-442332a961e6bb4bfde8 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Endoxifen 10V, Positive-QTOF | splash10-00di-0019000000-d78eeafe19daa54ddac9 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Endoxifen 20V, Positive-QTOF | splash10-05fr-1149000000-e1df0c6d8dfb9b328713 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Endoxifen 40V, Positive-QTOF | splash10-066u-9823000000-06951b7a731996b904ce | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Endoxifen 10V, Negative-QTOF | splash10-00di-0009000000-b38f885c98c9697e45e8 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Endoxifen 20V, Negative-QTOF | splash10-00xr-0019000000-bbed0c38c9db23b2f1cd | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Endoxifen 40V, Negative-QTOF | splash10-02ta-0089000000-32d3e92619afbb528e2a | 2021-10-12 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Ribeiro MP, Silva FS, Santos AE, Santos MS, Custodio JB: The antiestrogen endoxifen protects rat liver mitochondria from permeability transition pore opening and oxidative stress at concentrations that do not affect the phosphorylation efficiency. Toxicol Appl Pharmacol. 2013 Feb 15;267(1):104-12. doi: 10.1016/j.taap.2012.12.012. Epub 2012 Dec 27. [PubMed:23274567 ]
- Yang G, Nowsheen S, Aziz K, Georgakilas AG: Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacol Ther. 2013 Sep;139(3):392-404. doi: 10.1016/j.pharmthera.2013.05.005. Epub 2013 May 24. [PubMed:23711794 ]
- Binkhorst L, Mathijssen RH, van Herk-Sukel MP, Bannink M, Jager A, Wiemer EA, van Gelder T: Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat. 2013 Jun;139(3):923-9. doi: 10.1007/s10549-013-2585-z. Epub 2013 Jun 13. [PubMed:23760858 ]
|
|---|